ClinicalTrials.gg

Hepatitis B clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,046 studies for Hepatitis B across more than 10 countries. 139 are recruiting or about to start. 591 of them are mainly about Hepatitis B (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Hepatitis B, Chronic too: 1,777 studies, 257 open.

ClinicalTrials.gov finds 2,075 studies for Hepatitis B. How that becomes 1,045 here

This page counts the studies the registry files under Hepatitis B, and those it files under no condition that list Hepatitis Bthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,075Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −730Filed under a narrower condition, counted on its own pageHepatitis B, Chronic 700
  3. −23List Hepatitis B as a condition, but the registry did not file them under itMost often written as “Cirrhosis Due to Hepatitis B” (6), “Hepatitis B Reactivation” (2), and “Hepatitis B Vaccination” (2). The registry filed them under other conditions only, most often Fibrosis (5) and Hepatitis (3).
  4. −277Match it another way205 name it in the title, 17 in a keyword, and 55 by a synonym or other text the search reads.
  5. 1,045The count on this page40 of them list Hepatitis B in their own words; the registry filed them under no condition.

Status

Completed
616
Status unknown
177
Recruiting
80
Terminated
58
Not yet recruiting
53
Active, not recruiting
30

Phase

Phase 3
199
Phase 4
184
Phase 2
174
Phase 1
111
Early Phase 1
4

Where

United States
197
China
192
Canada
84
France
80
Korea, Republic of
77
Taiwan
73

Who develops what

Add Hepatitis B to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 18 programs from 17 companies, 7 with this as their studies’ main aim; 4 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Ausper Biopharma, GlaxoSmithKline and Grifols here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TenofovirRecent, repeated
Evidence
  • NCT06963710 · Aligos Therapeutics · Phase 2 · live · comparator · “TDF” · registered Apr 2025
  • NCT05612581 · Vir Biotechnology, Inc. · Phase 2 · background · “TDF” · registered Nov 2022
  • NCT04585789 · Johnson & Johnson · Phase 2 · background · “Tenofovir disoproxil” · registered Oct 2020
  • NCT04202536 · IlDong Pharmaceutical Co Ltd · Phase 4 · comparator · “Tenofovir disoproxil fumarate(TDF)” · registered Dec 2019
  • NCT02888106 · Hepatera Ltd. · Phase 2 · background · “Tenofovir” · registered Aug 2016
Gilead Sciences38% of its industry studiesUS: off-patent, 27 generics marketedEU: off-patent, 2 generics authorized22 studies

14 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
In-house Hepatitis B Vaccine☆ Track1 live phase-3 study: NCT07854847PT Bio Farma

The 1 in phase 3 with the nearest primary completion, of 18 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.solizmestrocel · beijing tuohua weiye biotechnology co ltd · Phase 2 main aimNCT07413549 Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis — primary endpoint: Incidence and characteristics of any adverse events and serious adverse events associated with human umbilical cord mesenchymal stem cell injection therapy · 76 enrolled
  • Feb 2027 est.In-house Hepatitis B Vaccine · PT Bio Farma · Phase 3 main aimNCT07854847 Study Interchangeability Hep-B Vaccine Administered at Birth Dose — primary endpoint: Protectivity of primary series In-House Recombinant Hepatitis B vaccine · 270 enrolled
  • Mar 2027 est.pevifoscorvir sodium · Aligos Therapeutics · Phase 2 named, not the main aimvs TenofovirNCT06963710 A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) — primary endpoint: HBeAg positive: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target detected or target not detected) · 200 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hepatitis B studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Reverse transcriptase inhibitors 67 · Statins 3

Coming up

44studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger. 14 (18%) take children under 18. 5 (6%) are for women only and 1 (1%) for men only; 20 (25%) take healthy volunteers.

Recruiting studies that take each age, of 80
AgeWomenMen
1010 (13%)8 (10%)
1871 (89%)68 (85%)
3075 (94%)71 (89%)
4074 (93%)70 (88%)
5073 (91%)70 (88%)
6567 (84%)66 (83%)
7548 (60%)47 (59%)
8542 (53%)41 (51%)

Across all 1,046 studies, recruiting or not: 58% stop at 75 or younger and 44% at 65; 31% take children; 5% are for women only and 2% for men only; 39% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hepatitis B studies take

Of 63 phase 4 interventional studies under Hepatitis B, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 114 mo7–27 · 58 studies13 mo7–24 · 49 studies—
Phase 230 mo19–40 · 50 studies33 mo19–40 · 40 studies—
Phase 315 mo9–34 · 50 studies13 mo9–23 · 42 studies—
Phase 435 mo12–59 · 63 studies—42 mo17–66 · 47 studies
Interventional, no phase29 mo11–47 · 68 studies—30 mo11–47 · 62 studies
Observational55 mo17–126 · 81 studies—59 mo17–126 · 69 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,046. Browse all 1,046 → or search them.